1. Park Jung Su retinoic acid (trademark is Totino)
Park Jung Su Vitone (trade name Toctino), a drug developed by Brasilia Pharmaceutical Company to treat severe chronic hand eczema, is the only drug in the world that can still play a healing role after all conventional steroid therapy drugs fail. The drug has been listed in 19 countries around the world (mainly located in the high incidence areas of hand eczema in Europe and America).
2. Cefodipropyl Ether
Cefodiloprolol is a broad-spectrum cephalosporin antibiotic, which is used to treat methicillin-resistant Staphylococcus aureus. Clinical research shows that it has a good inhibitory effect on multi-drug resistant Gram-positive bacteria and negative bacteria, and has a good therapeutic effect on complicated skin and skin structure infections and severe pneumonia. Basilia has completed phase III clinical trials of the drug in the European Union and the United States. At present, the relevant data are being reviewed by the European Union and the FDA of the United States, and the company announced that it will submit a listing application on 20 12.
3. Aisaconazole
Isuzonazole is a water-soluble broad-spectrum fungal inhibitor, and clinical research shows that it has excellent curative effect on many serious fungal infections. To this end, the FDA of the United States has specially approved a fast-track designation to accelerate the clinical research of this drug and promote the early listing of this drug. At present, the third phase clinical trial of the drug has been completed and is waiting for FDA approval.